Astrazeneca (AZNCF) Gains from Investment Securities (2016 - 2025)
Historic Gains from Investment Securities for Astrazeneca (AZNCF) over the last 15 years, with Q4 2025 value amounting to -$652.0 million.
- Astrazeneca's Gains from Investment Securities rose 1554.4% to -$652.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$2.8 billion, marking a year-over-year decrease of 345.45%. This contributed to the annual value of -$2.8 billion for FY2025, which is 345.45% down from last year.
- Latest data reveals that Astrazeneca reported Gains from Investment Securities of -$652.0 million as of Q4 2025, which was up 1554.4% from -$644.0 million recorded in Q3 2025.
- In the past 5 years, Astrazeneca's Gains from Investment Securities registered a high of $1.2 billion during Q4 2021, and its lowest value of -$1.2 billion during Q2 2025.
- Its 5-year average for Gains from Investment Securities is -$479.1 million, with a median of -$642.5 million in 2024.
- In the last 5 years, Astrazeneca's Gains from Investment Securities skyrocketed by 9811.32% in 2021 and then crashed by 243333.33% in 2022.
- Quarter analysis of 5 years shows Astrazeneca's Gains from Investment Securities stood at $1.2 billion in 2021, then plummeted by 165.16% to -$778.0 million in 2022, then fell by 7.46% to -$836.0 million in 2023, then increased by 7.66% to -$772.0 million in 2024, then rose by 15.54% to -$652.0 million in 2025.
- Its last three reported values are -$652.0 million in Q4 2025, -$644.0 million for Q3 2025, and -$1.2 billion during Q2 2025.